1. Long-term entecavir treatment is associated with an excellent virologic response and a low rate of entecavir-resistant mutation.
2. Baseline hepatitis B virus DNA load, quantitative hepatitis B surface antigen levels, and hepatitis B e antigen status are predictors of virologic response of entecavir treatment.
1. Negative pathologic diagnosis (NPD) after endoscopic resection (ER) resulted from either the complete removal of the lesion via forceps biopsy, or the misinterpretation of the samples.
2. More than half of the NPD lesions after ER were diagnosed as pit dysplasia (PD) after review.
3. PD can partly explain the frequent occurrence of NPD after ER, and the use of PD can reduce the diagnostic discrepancy between the initial forceps biopsy and ER specimens.
1. The Livalo in Acute Myocardial Infarction Study (LAMIS)-II is the first study which was conducted for the evaluation of the incidence of cardiovascular events and effects on lipid profiles and glucose tolerance with two doses of pitavastatins in Korean acute myocardial infarction patients.
2. The LAMIS-II demonstrated very low incidences of cardiac mortality and all-cause mortality by using both 2 and 4 mg of pitavastatins.
3. The LAMIS-II demonstrated that the incidences of major adverse cardiovascular event were not significantly different between 2 and 4 mg of pitavastatin groups.
4. The LAMIS-II demonstrated that both 2 and 4 mg of pitavastatin treatment reduced low density lipoprotein cholesterol effectively without adverse effects on glucose tolerance from baseline to 12-month follow-up.